The heterodimeric cytokine interleukin 27 (IL-27) signals through the IL-27Rα subunit of its receptor, combined with gp130, a common receptor chain used by several cytokines, including IL-6. Notably, the IL-27 subunits p28 (IL-27p28) and EBI3 are not always expressed together, which suggests that they may have unique functions. Here we show that IL-27p28, independently of EBI3, antagonized cytokine signaling through gp130 and IL-6-mediated production of IL-17 and IL-10. Similarly, the ability to generate antibody responses was dependent on the activity of gp130-signaling cytokines. Mice transgenic for expression of IL-27p28 showed a substantial defect in the formation of germinal centers and antibody production. Thus, IL-27p28, as a natural antagonist of gp130-mediated signaling, may be useful as a therapeutic for managing inflammation mediated by cytokines that signal through gp130.
A role for IL-27p28 as an antagonist of gp130-mediated signaling
J. Stumhofer,Elia D. Tait,W. Quinn,N. Hosken,Björn Spudy,Radhika Goenka,C. Fielding,A. O’Hara,Yi Chen,Michael L. Jones,C. Saris,S. Rose-John,D. Cua,Simon A. Jones,M. Elloso,J. Grötzinger,M. Cancro,S. Levin,C. Hunter
Published 2010 in Nature Immunology
ABSTRACT
PUBLICATION RECORD
- Publication year
2010
- Venue
Nature Immunology
- Publication date
2010-10-14
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-64 of 64 references · Page 1 of 1